Quest Diagnostics Incorporated (NYSE:DGX) Director Jeffrey M. Leiden Sells 296 Shares
Quest Diagnostics Incorporated (NYSE:DGX) Director Jeffrey M. Leiden sold 296 shares of Quest Diagnostics stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $106.66, for a total transaction of $31,571.36. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at approximately $639,960. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Quest Diagnostics Incorporated (NYSE:DGX) traded down 0.49% during midday trading on Tuesday, reaching $106.21. 885,017 shares of the company’s stock traded hands. The firm has a market capitalization of $14.49 billion, a PE ratio of 21.40 and a beta of 0.69. The stock’s 50-day moving average price is $109.15 and its 200 day moving average price is $102.52. Quest Diagnostics Incorporated has a one year low of $79.12 and a one year high of $112.97.
Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.13. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 EPS. On average, equities research analysts expect that Quest Diagnostics Incorporated will post $5.69 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Monday, July 24th. Investors of record on Monday, July 10th were given a $0.45 dividend. The ex-dividend date was Thursday, July 6th. This represents a $1.80 dividend on an annualized basis and a yield of 1.69%. Quest Diagnostics’s dividend payout ratio is presently 36.29%.
WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/quest-diagnostics-incorporated-nysedgx-director-jeffrey-m-leiden-sells-296-shares.html.
A number of research firms have recently commented on DGX. BidaskClub upgraded shares of Quest Diagnostics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 29th. UBS AG raised their price objective on shares of Quest Diagnostics from $115.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 6th. Mizuho raised their price objective on shares of Quest Diagnostics from $115.00 to $122.00 and gave the company a “buy” rating in a research report on Monday, June 5th. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. Finally, Barclays PLC restated a “hold” rating and issued a $110.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, July 19th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $110.72.
Several hedge funds have recently added to or reduced their stakes in the company. Teachers Advisors LLC increased its stake in Quest Diagnostics by 6.6% in the fourth quarter. Teachers Advisors LLC now owns 177,243 shares of the medical research company’s stock valued at $16,289,000 after buying an additional 11,003 shares during the period. Chevy Chase Trust Holdings Inc. raised its position in shares of Quest Diagnostics by 2.3% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 118,823 shares of the medical research company’s stock valued at $11,667,000 after buying an additional 2,668 shares in the last quarter. Creative Planning raised its position in shares of Quest Diagnostics by 30.8% in the first quarter. Creative Planning now owns 4,159 shares of the medical research company’s stock valued at $408,000 after buying an additional 980 shares in the last quarter. Gulf International Bank UK Ltd raised its position in shares of Quest Diagnostics by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 45,053 shares of the medical research company’s stock valued at $4,423,000 after buying an additional 625 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Quest Diagnostics by 3.1% in the first quarter. Bank of Montreal Can now owns 292,342 shares of the medical research company’s stock valued at $28,705,000 after buying an additional 8,700 shares in the last quarter. Institutional investors and hedge funds own 90.97% of the company’s stock.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.